Antigen News and Research

RSS

Cytek® Biosciences automates panel design with new intelligent algorithm

With the SpectroPanel tool, Cytek Cloud transforms flow cytometry panel design, enabling rapid optimization and enhancing research capabilities for scientists.

From Cytek Biosciences 23 Aug 2024

Olaparib effective against BRCA2-mutated prostate cancer

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.

23 Aug 2024

Probiotic offers protection against intestinal damage

There is a critical unmet need to help tighten and maintain a healthy intestinal barrier and treat a leaky gut. Researchers have now found that a unique strain of probiotic bacteria, Bifidobacterium bifidum BB1, enhances intestinal barrier function and protects against penetration of bacteria and various harmful agents in the intestine. The findings, detailed in an article in The American Journal of Pathology, published by Elsevier, can help advance the development of novel, targeted, naturally occurring probiotic therapy for patients with inflammatory bowel disease (IBD) and other inflammatory diseases, such as fatty liver disease or alcoholic liver disease, that are associated with a leaky or disordered intestinal barrier.

23 Aug 2024

Understanding gluten's role in autoimmunity and inflammation

The interaction between humans and their environment, mediated by nutrition, plays a crucial role in regulating inflammatory responses.

21 Aug 2024

UC Davis researchers unveil pathway for Salmonella's gut invasion

How do bad bacteria find entry points in the body to cause infection? This question is fundamental for infectious disease experts and people who study bacteria.

20 Aug 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

New project aims to study the combination of two therapies for pediatric brain cancer

Natasha Sheybani, assistant professor of biomedical engineering at the University of Virginia School of Engineering, will collaborate with researchers at Children's National Hospital to study the combination of two therapies for pediatric brain cancer.

19 Aug 2024

Long COVID symptoms may stem from low cortisol and altered brain immune response

Proteins left behind by COVID-19 long after initial infection can cause cortisol levels in the brain to plummet, inflame the nervous system and prime its immune cells to hyper-react when another stressor arises, according to new animal research by University of Colorado Boulder scientists.

19 Aug 2024

New trial explores BAFF CAR T-cell therapy for relapsed myeloma

University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial.

14 Aug 2024

EZH2's role in cancer progression and therapy explored

Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).

9 Aug 2024

Study links renalase-1 and T-cell receptor interaction to increased melanoma survival

A new research paper was published in Oncotarget's Volume 15 on August 5, 2024, entitled, "Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival."

8 Aug 2024

High BPA levels linked to increased prostate cancer risk in older men

A study in Nutrients found that higher urinary bisphenol A (BPA) levels are linked to increased prostate-specific antigen (PSA) and higher prostate cancer risk in senior American men. This suggests a need for heightened cancer screening, especially in high-risk groups.

8 Aug 2024

New research uncovers mechanisms behind heart damage from CTLA-4 blockade

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells.

7 Aug 2024

Innovative nasal spray and vaccine for respiratory virus protection

A team of researchers, led by the University of Houston, has discovered two new ways of preventing and treating respiratory viruses.

6 Aug 2024

New target identified for melanoma resistant to current therapies

Some proteins, such as programmed cell death protein 1 (PD1), can stop the immune system from attacking cancer cells and, therefore, support the growth of cancer.

6 Aug 2024

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells.

5 Aug 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024